GlobeNewswire Inc | Sep 9, 2020 08:00AM EDT

September 09, 2020

BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference and the Cantor Fitzgerald Virtual Global Healthcare Conference.

H.C. Wainwright Annual Global Investment ConferenceDate: September 14Time: 2:30pm Eastern TimeWebcast: https://wsw.com/webcast/hcw7/vyne/1630674 Cantor Fitzgerald Virtual Global Healthcare ConferenceDate: September 16Time: 10:00am Eastern TimeWebcast: https://www.webcaster4.com/Webcast/Page/2495/37311

The Cantor Fitzgerald presentation will take the form of a Fireside Chat with analyst Louise Chen.

About VYNE Therapeutics Inc.VYNE Therapeutics mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.

With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST), and has received FDA approval for AMZEEQ (minocycline) topical foam, 4%, the worlds first topical minocycline, and for ZILXI (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. For more information about our approved products, please see AMZEEQs Full Prescribing Information at amzeeq.com and ZILXIs Full Prescribing Information at zilxi.com.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www. vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNEs website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:Joyce AllaireLifeSci Advisors, LLC646-889-1200jallaire@lifesciadvisors.com

Andrew SaikChief Financial OfficerVYNE Therapeutics908-731-6180Andrew.Saik@vynetx.com